drugset
drugset / Trial / NCT02435108

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

NCT02435108 ↗

Phase 2 Completed 2 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

This is a pilot study of crizotinib in patients with c-MET positive gastric adenocarcinoma.

Timeline

Start
2014-05-15
Primary completion
2016-01
Completion
2016-07-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule 250 mg —

Indications

No indication recorded.